NCT01334567View on ClinicalTrials.gov

Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in Taiwan

PHASE2CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Hepatitis B

Interventions

DRUG

Tenofovir DF

Provision of tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablets, as prescribed by study investigators

Trial Locations (4)

Unknown

Kaoshiung Hsien

Tainan City

Taipei

Taoyuan Hsien

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY

NCT01334567 - Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in Taiwan | Biotech Hunter | Biotech Hunter